Sarah and Ira and ASH 2019

Highlights from the American Society of Haematology 2019

The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. It was attended by over 30,000 scientists and clinicians from around the world and covered around 6,000 topics with over 700 myeloma abstracts. Here are some of our highlights from this year’s meeting. Myeloma XI There were five…

Details
Amy Capper and Daniel Cairns at the Scottish Cancer Conference

Highlights from the Scottish Cancer Conference 2019

The annual Scottish Cancer Conference was held in Glasgow on 18 November 2019. It was a unique gathering of organisations involved with cancer, including patients, pharmaceutical companies, clinicians and charities. It presented an opportunity to share, learn and network, as well as understand the latest developments in Scotland’s combined efforts to beat cancer. This year…

Details
myeloma bone marrow aspirate

Highlights from the 2nd Oxford Myeloma Workshop

The 2nd Oxford Myeloma Workshop was a two-day event (1-2 August 2019) run by Oxford University Hospitals which focused on the current translational research priorities in myeloma. Patient Advocacy and Policy Research Officer, Dr Amy Capper was there to learn about the latest developments. Here are some of her highlights from the programme: Opening the…

Details

Highlights from the 2019 UK Myeloma Forum Scientific Workshop

The UK Myeloma Forum (UKMF) is a collaborative organisation of healthcare professionals and scientists which aims to improve the treatment of patients with myeloma. The annual UKMF Scientific Workshop is an all-day event where leading experts share the latest biomedical research aiming to improve understanding of myeloma and develop new strategies to improve patient outcomes. This year’s…

Details

60th American Society of Haematology Annual Meeting (ASH) Research Highlights

OPTIMISING CURRENT TREATMENTS The number of drugs available as myeloma treatment has grown significantly over the last two decades with discovery and approval of immunomodulatory drugs (thalidomide, lenalidomide (Revlimid®) and pomalidomide (Imnovid®)), proteasome inhibitors (bortezomib (Velcade®), cafilzomib (Kyprolis®) and ixazomib (Ninlaro®)), histone deacetylase inhibitors (panobinostat) and monoclonal antibody drugs (daratumumab (Darzalex®) and elotuzumab (Empliciti®)). However,…

Details